WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010115916) PROCESS FOR ISOLATING THERAPEUTIC PEPTIDE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/115916    International Application No.:    PCT/EP2010/054577
Publication Date: 14.10.2010 International Filing Date: 07.04.2010
IPC:
C07K 7/08 (2006.01), C07K 14/245 (2006.01)
Applicants: ROCHE BOULDER CORPORATION [US/US]; 2075 North 55th Street Boulder, CO 80301-2880 (US) (For All Designated States Except US).
FLEMING, Michael Paul [US/US]; (US) (For US Only).
PETERSEN, Raymond Dennis [US/US]; (US) (For US Only)
Inventors: FLEMING, Michael Paul; (US).
PETERSEN, Raymond Dennis; (US)
Agent: KUENG, Peter; Grenzacherstrasse 124 CH-4070 Basel (CH)
Priority Data:
61/168,259 10.04.2009 US
Title (EN) PROCESS FOR ISOLATING THERAPEUTIC PEPTIDE
(FR) PROCÉDÉ D'ISOLEMENT D'UN PEPTIDE THÉRAPEUTIQUE
Abstract: front page image
(EN)Disclosed are methods of isolating linaclotide, a cyclized 14-amino-acid peptide with three disulfide bonds. The sequence consists of Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr (SEQ ID NO 1) with disulfide bridges between the cysteine residues at positions 1 and 6, 2 and 10, and 5 and 13. The drug acts as a GCC superagonist, elevating intracellular cGMP composition for treating various disorders, including gastrointestinal disorders, obesity, congestive heart failure and benign prostatic hyperplasia.
(FR)L'invention porte sur des procédés d'isolement de linaclotide, un peptide cyclisé à 14 acides aminés avec trois liaisons disulfure. La séquence consiste en Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly- Cys-Tyr (SEQ ID N°1) avec des ponts disulfure entre les résidus de cystéines aux positions 1 et 6, 2 et 10 et 5 et 13. Le médicament agit en tant que composition superagoniste de GCC, augmentant le GMPc intracellulaire pour traiter divers troubles, comprenant des troubles gastro-intestinaux, l'obésité, une insuffisance cardiaque congestive et une hyperplasie prostatique bénigne.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)